An underlying explanation might be the fact that FGF21 levels are elevated in individuals with subclinical atherosclerosis, diabetes mellitus, and nonalcoholic fatty liver disease [68]. This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatotic liver disease.